Clinical trials: Alzheimer's
Health Related Social Needs (HRSN)
CommunityRx-Dementia
Caregivers of home-dwelling people with Alzheimer's Disease and related dementias (ADRD) are one of the most rapidly growing populations in the United States.
- Trial name
- CRx-D (NCT04146545)
- Testing
- Community Rx-Dementia "CRxD" Caregiver Resources
- Where
- United States
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Alzheimer Disease, Alzheimer Disease (AD)
Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine
This Phase 1 clinical trial evaluates the safety, tolerability, and immune response of the adjuvanted AV-1959R vaccine in healthy adults aged 40-60.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Alzheimers Disease Prevention
- Trial name
- NCT06831812
- Testing
- AV-1959R (Abeta vaccine)
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Mild Cognitive Impairment (MCI), Alzheimer Disease
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT05108922
- Testing
- Donanemab, Aducanumab
- Where
- 31 sites in United States
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Feasibility - Infinitome
The Infinitome Program from Omniscient has the ability to identify abnormal brain networks or connectomes using resting state functional MRI (rs-fMRI).
- Trial name
- NCT04563767
- Testing
- Infinitome
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- HealthPartners Institute
Alzheimer's Disease
Evaluation of Physician Training Methods to Read Florbetapir-PET Scans
The purpose of this study is re-read of brain amyloid positron emission tomography (PET) scans acquired in previous florbetapir F 18 clinical studies by readers trained using updated reading methodology.
- Trial name
- NCT01565369
- Testing
- florbetapir F 18
- Volunteers
- 35 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease or Vascular Dementia
A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia
A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient with Alzheimer's Disease or Vascular Dementia
- Trial name
- NCT02886494
- Testing
- BAC treatment, Matched vehicle
- Where
- 10 sites in United States
- Volunteers
- 80 people
- Sponsor
- Charsire Biotechnology Corp.
Sleep Initiation and Maintenance Disorders
Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
The aim of this study is to demonstrate the efficacy of timed exposure to bright light for the treatment of disturbed nighttime sleep and daytime wake in community-dwelling dementia patients and their caregivers, and to determine…
- Trial name
- NCT00946530
- Testing
- Bright light, Control
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Stanford University
Alzheimer Disease
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort.
- Trial name
- NCT04437511
- Testing
- Donanemab
- Where
- 274 sites in United States, Australia and 7 more
- Volunteers
- 1,736 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease, Mild Cognitive Impairment
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
- Trial name
- NCT00702143
- Testing
- florbetapir F 18
- Where
- 15 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
- Trial name
- NCT00934050
- Testing
- ELND005 (scyllo-inositol)
- Where
- 38 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- OPKO Health, Inc.
Alzheimer's Disease
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
This multi-center, randomized, double-blind, placebo-controlled parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in participants with…
- Trial name
- Scarlet Road (NCT01224106)
- Testing
- Gantenerumab
- Where
- 139 sites in United States, Argentina and 22 more
- Volunteers
- 799 people
- Sponsor
- Hoffmann-La Roche
Mild Cognitive Impairment
Rhythmic Light Therapy for Alzheimer's Disease Patients
The investigator will investigate how light delivering 40 hertz (Hz) affects subjective sleep and cognition in a controlled laboratory study.
- Trial name
- NCT05015478
- Testing
- Tailored Rhythmic Lighting Intervention
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alzheimer's Disease
Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease
This study is being done to evaluate the safety, tolerability and potential effectiveness of a new investigational drug, bryostatin 1, in patients with Alzheimer's disease (AD).
- Trial name
- NCT02221947
- Testing
- Bryostatin 1
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Neurotrope Bioscience, Inc.
Amyotrophic Lateral Sclerosis, Alzheimer Disease
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
This is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), or asymptomatic carriers…
- Conditions
- Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NADALS (NCT05189106)
- Testing
- Baricitinib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Alzheimer's Disease
Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease
By doing this study, researchers will examine the safety and tolerability of R-pramipexole in participants with Alzheimer's disease.
- Trial name
- NCT01388478
- Testing
- R-pramipexole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University